SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the Canaccord Adams 29th Annual Global Growth Conference at the Intercontinental Hotel in Boston on August 13, 2009, 2:00 p.m. Eastern Time.
Live audio webcasts of these presentations will be accessible on the Company's website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Contacts Optimer Pharmaceuticals, Inc. Christina Donaghy, Corporate Communications Manager John D. Prunty, Chief Financial Officer & VP Finance 858-909-0736 Porter Novelli Life Sciences Jason I. Spark, Vice President 619-849-6005
|SOURCE Optimer Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved